FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

ANDERSON MICHAEL S 		2. Issuer Name and Ticker or Trading Symbol

FLAMEL TECHNOLOGIES SA [ FLML ] 		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

__ X __ Director                      _____ 10% Owner
__ X __ Officer (give title below)      _____ Other (specify below)
Chief Executive Officer
(Last)          (First)          (Middle)

33, AVENUE DU DOCTEUR GEORGES LEVY 		3. Date of Earliest Transaction (MM/DD/YYYY)

11/21/2016
(Street)

VENISSIEUX, I0 69200
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
ADSs   (1) 11/21/2016     P    2000   A $10.637   (2) 193250   (3) D    

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3) 		2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8) 		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4) 		8. Price of Derivative Security
(Instr. 5) 		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (right to buy)   $6.93                      (4) 3/8/2022   ADSs   275000     275000   D    
Stock Option (right to buy)   $4.07                      (5) 2/1/2023   ADSs   80500     80500   D    
Stock Option (right to buy)   $16.3                      (6) 12/11/2024   ADSs   200000     200000   D    
Stock Option (right to buy)   $14.35                      (7) 12/10/2025   ADSs   200000     200000   D    

Explanation of Responses:
( 1)  The issuer's "ADSs" are American Depositary Shares, with each ADS representing one ordinary share, nominal value 0.122 Euros per share, of the issuer; ADSs are represented by American Depositary Receipts.
( 2)  The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $10.625 to $10.64, inclusive. The reporting person undertakes to provide to Flamel Technologies S.A., any security holder of Flamel Technologies S.A., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (2).
( 3)  Includes (a) 50,000 restricted ADSs granted under the issuer's "Free Share" award program on 12/11/2014, all of which will be issued to the reporting person on the fourth anniversary of the grant date, provided that the reporting person continues to be employed by the issuer or an affiliate thereof on the second anniversary of the grant date; and (b) 50,000 restricted ADSs granted under the issuer's "Free Share" award program on 8/10/2016, all of which will be issued to the reporting person on the second anniversary of the grant date.
( 4)  Options became exercisable in four equal amounts over the first four anniversaries after the 03/08/2012 grant date.
( 5)  Options become exercisable as to 20,125 ADSs on each of the first four anniversaries after the 02/01/2013 grant date.
( 6)  Options become exercisable as to 50,000 ADSs on each of the first four anniversaries after the 12/11/2014 grant date.
( 7)  Options become exercisable as to 50,000 ADSs on each of the first four anniversaries after the 12/10/2015 grant date.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
ANDERSON MICHAEL S
33, AVENUE DU DOCTEUR GEORGES LEVY
VENISSIEUX, I0 69200 		X
Chief Executive Officer

Signatures
/s/ Phillandas T. Thompson, as attorney-in-fact for Michael S. Anderson 11/22/2016
** Signature of Reporting Person Date


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Avadel Pharmaceuticals (NASDAQ:AVDL)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Avadel Pharmaceuticals Charts.
Avadel Pharmaceuticals (NASDAQ:AVDL)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Avadel Pharmaceuticals Charts.